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Abstract
The neuropeptide S receptor (NPSR) is a recently deorphanized member of the G protein-coupled receptor (GPCR)
superfamily and is activated by the neuropeptide S (NPS). NPSR and NPS are widely expressed in central nervous system and
are known to have crucial roles in asthma pathogenesis, locomotor activity, wakefulness, anxiety and food intake. The NPS-
NPSR system was previously thought to have first evolved in the tetrapods. Here we examine the origin and the molecular
evolution of the NPSR using in-silico comparative analyses and document the molecular basis of divergence of the NPSR
from its closest vertebrate paralogs. In this study, NPSR-like sequences have been identified in a hemichordate and a
cephalochordate, suggesting an earlier emergence of a NPSR-like sequence in the metazoan lineage. Phylogenetic analyses
revealed that the NPSR is most closely related to the invertebrate cardioacceleratory peptide receptor (CCAPR) and the
group of vasopressin-like receptors. Gene structure features were congruent with the phylogenetic clustering and
supported the orthology of NPSR to the invertebrate NPSR-like and CCAPR. A site-specific analysis between the vertebrate
NPSR and the well studied paralogous vasopressin-like receptor subtypes revealed several putative amino acid sites that
may account for the observed functional divergence between them. The data can facilitate experimental studies aiming at
deciphering the common features as well as those related to ligand binding and signal transduction processes specific to
the NPSR.
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Introduction
The neuropeptide S receptor (NPSR, formerly GPR154), a
seven transmembrane spanning G-protein coupled receptor
(GPCR) is activated by an endogenous 20 amino acid peptide
known as neuropeptide S (NPS) [1–4]. The NPSR is widely
distributed throughout the central nervous system (CNS) [3,5].
NPSR mRNA expression is present in many regions in the brain
that are associated with regulation of the stress response, memory,
the olfactory system and regulation of arousal. In contrast, NPS
precursor mRNA is found in isolated cells of the amygdala and the
dorsomedial hypothalamic nucleus and especially confined to
specific regions of the brainstem including the Barrington’s
nucleus in the principal sensory trigeminal nucleus, the lateral
parabrachial nucleus and a previously undescribed area adjacent
to the locus coeruleus (peri-LC) [6]. NPS binds to NPSR with high
affinity and activates both Gq and Gs proteins, leading to increase
in free intracellular calcium and cyclic adenosine monophosphate
(cAMP) accumulation in cell lines that express NPSR [3,7,8]. Very
little is known regarding the biochemical and physiological roles of
the NPS-NPSR system. Functionally, central dispensation of NPS
produces strong anxiolytic-like behavior, increase in wakefulness
and locomotor activity and enhances spatial memory and
produces anti-nociceptive effects to thermal stimuli in mice [3,9–
14]. In line with NPSR expression in the hypothalamus, a key
brain region for the regulation of food intake, a recent report
demonstrated an inhibitory effect of NPS given intracerebroven-
tricularly on food intake in rats [10].
Multiple isoforms of human NPSR have been reported as
products of alternative splicing of NPSR mRNA [2]. Seven
transmembrane topology characteristic of GPCRs is encoded only
by three isoforms of NPSR variants, of which two variants produce
functional receptors that are trafficked to the cell membrane, as
demonstrated by current evidence [15]. Multiple single nucleotide
polymorphisms (SNPs) have also been identified in human NPSR
receptor gene and those are associated with risks of asthma and
bronchial hyper-responsiveness [2,16,17]. Moreover, the NPSR
gene was recognized as a representative gene for specific
haplotypes in the human NPSR locus that have been associated
with a number of allergic or immunological disorders such as
rhinoconjunctivitis, respiratory distress syndrome and irritable
bowel syndrome [18–20]. For instance, one SNP leading to an
Asn/Ile exchange in NPSR results in a 5 to 10-fold increased
agonist sensitivity without affecting binding affinity [17,21,22].
Potent NPSR antagonists identified recently blunt NPS-mediated
arousal and anxiolytic-like effects and might have clinical
applications in the treatment of obesity, hypersomia and anxiety
disorders without causing sedation [14,22–24].
A previous bioinformatic analysis of NPS sequences revealed
that the NPS precursor is highly conserved and is present in all
vertebrates with the exception of the ray-finned fish (Actinopter-
ygii). The NPS thus appeared to be specific to tetrapods, including
mammals, birds, reptiles and amphibian [25]. However, a novel
family of neurophysin-associated neuropeptides (NG peptides),
was recently discovered in invertebrate deuterostomes but not in
vertebrates, urochordates, protostomes or cnidarians. Interesting-
ly, the NG peptides, so called because of a conserved sequence
motif NG, share strong sequence similarity to the N-terminal
region of NPS and is suggestive of a probable evolutionary link
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formerly named vasopressin receptor-related receptor (VRR1), is a
recently deorphanized GPCR with limited knowledge of the mode
of evolution and its divergence from other neuropeptide receptors.
NPSR orthologs have been identified in several tetrapod genomes
and is consistent with the evolution of its ligand NPS. The closest
vertebrate homologs of NPSR are the vasopressin-like receptors.
For instance, in a BLAST search, the human NPSR shares about
28 to 34% amino acid sequence identity with the human
vasopressin-like receptor subtypes. In this study, using comparative
sequence analyses, we sought to: 1) identify NPSR homologs
across the metazoan genomes, 2) address the phylogenetic
relationship of NPSR with other known neuropeptide receptors
to follow the origin and evolution of the NPS associated receptor
system and 3) analyze the sites responsible for the evolution of
functional divergence between the NPSR and the relatively well
studied paralogous vasopressin-like receptor sequences.
Methods
Identification of NPS receptors
All known neuropeptide S receptor sequences from the GPCR
Database, GPCRDB version 11.3.4 (http://www.gpcr.org/7tm/)
[27], UniProt–Protein Knowledgebase (UniProtKB (http://www.
uniprot.org/) and Ensembl (http://www.ensemblgenomes.org/)
were first obtained. These sequences were used to build a profile
using hidden Markov model (HMM) program HMMBUILD and
was calibrated using HMMCALIBRATE. This HMM profile was
used as a query in the HMMSEARCH program (E value cut
off=1e-5) to search the 65 proteomes downloaded from Ensembl
and Joint Genome Institute (JGI) (http://www.jgi.doe.gov/)
databases. All HMM based programs were run locally using the
HMMER suite of programs with default parameters [28].
Simultaneously, a BLAST search (E value cut-off=1e-5) was
performed using confirmed sequences against UniProtKB and the
non-redundant NCBI database. Additionally, the HMMSEARCH
against non-redundant NCBI and UniProtKB database was
performed using Mobyle Portal server (http://mobyle.pasteur.fr/
cgi-bin/portal.py) [29]. Assignment of NPSR orthology for
putative hits obtained from the HMMSEARCH and BLAST
searches was considered if it had known NPSRs as top 5 hits in a
reciprocal BLAST search of the entire GPCRDB. The retrieved
NPSR sequences were refined using Cluster Database at High
Identity with Tolerance (CD-hit) program, with a word size of 5
and 95% identity as the clustering threshold to remove redundant
sequences and pseudogenes [30]. The sequences were examined
for transmembrane helices using the TMHMM program (http://
www.cbs.dtu.dk/services/TMHMM/) [31]. Sequences having 7
transmembrane helices and those with 6 transmembrane helices
were retained assuming that either the last transmembrane might
be shorter or missing, while the remaining sequences were
removed. The sequences were further manually scrutinized to
eliminate isoforms resulting from gene splice variants. Out of a
total of 42 sequences, several sequences contained stretches of
undetermined residues as a result of incomplete genome
information or possible errors in the automated splice site
prediction methods used (Table S1). The sequences from lizard
and dolphin were incomplete at the N- terminal, while the acorn
worm sequence was missing the C- terminal region. The lancelet
sequence was truncated at both the N- and C- termini. In this
study, these sequences were manually corrected to include missing
regions. The missing regions in each case was identified by the use
of translated alignments against their genomic regions where the
missing region was expected to be found based on alignment with
the human N- and C- termini. The final dataset contained 26
sequences of NPSR homologs from 26 organisms. Protein
sequences used in this study including the manually corrected
sequences are provided in Data S1.
Multiple sequence alignment and phylogenetic tree
construction
Multiple sequence alignment was generated for the final dataset
of NPSR sequences and with representatives from other
neuropeptide family receptors using MAFFT program, (http://
align.bmr.kyushu-u.ac.jp/mafft/online/server), with BLOSUM62
as the scoring matrix and using option G-INS-I for better accuracy
for the data set with global homology [32]. The pairwise sequence
identities were calculated from the multiple sequence alignments
over the entire alignment using the Geneious program [33].
Alignments of the sequences along with secondary structures were
displayed using ESPript 2.2 (http://espript.ibcp.fr) [34]. Phyloge-
netic trees were constructed using Maximum likelihood (ML)
and Bayesian methods. Maximum likelihood approach used to
infer phylogeny was implemented in MEGA version 5.0 [35].
Evolutionary model and parameters appropriate for phylogeny
was determined using ProtTest based on the Akaike Information
Criterion (minAIC) [36]. Jones-Taylor-Thornton amino acid
substitution matrix with frequency model along with gamma
distributed with invariant sites for rate among sites (JTT+I+G+F)
was obtained as the best model to determine the evolution for this
data set. Results that emerged in ProtTest were consistent with the
MEGA substitution model estimation. Robustness of tree topology
was measured by testing the phylogeny with 500 bootstrap
replications and default parameters were employed for rates, data
subset and tree interference options.
Phylogenetic analysis using the Bayesian approach was
performed by using MrBayes 3.1.2 [37] with gamma-distributed
rate variation and a proportion of invariant sites with frequencies,
using JTT model. Markov Chain Monte Carlo (MCMC) analysis
was used to approximate the posterior probabilities of the trees.
Analysis was run for 3000000 generations and every hundredth
tree was sampled. A stop rule was applied to terminate the
MCMC generations and convergence of MCMC was assessed
until the average standard deviation of split frequencies was
dropped below 0.01 (stop value). The first 25% of sampled trees
were disregarded as the burnin period so that parameter estimates
were only made from data drawn from distributions derived after
the MCMCs had converged. A consensus tree was built from the
remaining 75% of the sampled trees with sumt command using the
50% majority rule method. The sump command was used to
control so that an adequate sample of the posterior probability
distribution was reached during the MCMC procedure. The
phylogenetic trees were drawn in MEGA v5.0.
Analysis of gene structure and gene order
Gene structure analysis was carried out using Gene Structure
Display Server (GSDS) [38] (http://gsds.cbi.pku.edu.cn/). Coding
sequences and the corresponding genomic sequences were
submitted to the GSDS for generating the exon-intron map with
the intron phase information. The results from the server were
checked for compatibility with the information present for the
protein sequences in the Ensembl and JGI databases. The analysis
included a total of 24 NPSRs, 2 NPSR-like sequences and
representatives of the invertebrate CCAPRs and the vasopressin-
like receptor family for which gene structure information were
available. Intron positions and phases were mapped onto the
protein sequence alignment. Intron positions were deemed
conserved across the alignment for small changes in intron
Evolution of Neuropeptide S Receptor
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sequences that were manually corrected, including CCAPRs,
identification of intron positions were carried out using the online
splice site prediction server, SplicePredictor [40]. Analysis of
synteny was performed by manual examination and comparison of
chromosomal loci using genome browsers in the NCBI and
Ensembl databases.
Estimation of functional divergence
Functional divergence analysis between the vertebrate NPSR
and its closest vertebrate paralogs, the vasopressin-like receptor
family, was performed using Diverge2 program [41]. This method
is based on maximum likelihood procedures to estimate significant
changes in the site-specific shift of evolutionary rate after the
emergence of two paralogous sequences. Sites displaying Type I
and Type II functional divergence were identified using the
program. Type I divergence between two paralogous groups result
in amino acid sites that are highly conserved in one and are
variable in the other. In Type II divergence, amino acid sites are
highly conserved within the groups but have radically different
properties between the groups. Functional divergence tests are
based upon the coefficients of divergence (h), which is the
probability that a specific site has diverged in a pairwise
comparison. A h value significantly greater than zero, indicates
functional divergence. A posterior probability analysis was used to
identify individual sites likely contributing to functional divergence
[42]. The cut-off value for the posterior probability was
determined by consecutively eliminating the highest scoring sites
from the alignment until the h value dropped to close to zero.
Results and Discussion
Identification and distribution of the neuropeptide S
receptor
A total of 40 NPSR sequences were identified in vertebrates,
including 35 from mammals, 3 from birds and 1 each from
reptilian and amphibian species. NPSR orthologs were not
detected in several fish genomes including the ray-finned fishes,
the elephant shark (Callorhinchus milii), a cartilaginous fish that
represents the earliest jawed vertebrates, and the sea lamprey
(Petromyzon marinus), a jawless fish that represents the earliest extant
primitive vertebrates. Furthermore, the NPSR could not be
detected in invertebrates including the mollusks, ascidians,
annelids, insects or cnidaria. These observations are consistent
with an earlier study that reported the existence of the NPS
peptide only in the tetrapods [25]. Interestingly, sequence searches
indicated strong homology of the NPSR to the invertebrate
cardioacceleratory peptide receptors (CCAPR). In fact, in all
BLAST and HMM searches using a NPSR query sequence, the
CCAPRs were among the top non-NPSR hits along with the
vertebrate vasopressin-like receptors. The human NPSR shares a
sequence identity of about 44% with the Drosophila melanogaster
CCAPR. The vasopressin-like receptor subtypes include the
vertebrate vasopressin 1A (V1AR), vasopressin 1B (V1BR),
vasopressin 2 (V2R) and the oxytocin (OTR) receptors and their
invertebrate orthologs. In multiple sequence alignments carried
out using representative homologs, the NPSRs share pairwise
sequence identities in the range 21 to 28% and 22 to 36%, with
the vasopressin-like receptor subtypes and the CCAPRs, respec-
tively, over the entire sequence. However, NPSR shares better
homology when only the transmembrane regions were compared,
with identities in the range 23 to 31% and 30 to 43%, with the
vasopressin-like receptor subtypes and the CCAPRs, respectively.
It is noteworthy that two NPSR-like sequences were identified in a
cephalochordate (Branchiostoma floridae) and a hemichordate
(Saccoglossus kowalevskii). The two invertebrate deuterostome
NPSR-like sequences were considered for further analyses since
the reciprocal BLAST hits approach used in this study indicated
unambiguous one-to-one orthology to vertebrate NPSRs. The
sequence identities of lancelet (B. floridae) and acorn worm (S.
kowalevskii) NPSR-like sequences against the human NPSR are
about 49% and 38%, respectively. If the N- and C-terminal
regions were excluded, the identities of the lancelet and acorn
worm sequences increased to 56% and 46%, respectively. The
annotation of all putative homologs was subsequently confirmed
using phylogenetic analysis as described in the next section.
Phylogenetic analysis
Phylogenetic reconstruction using the Bayesian method was
employed to investigate the phylogenetic relationships of the
NPSR with other peptide receptors of the Rhodopsin family. We
used a diverse selection of receptors including the vertebrate and
invertebrate vasopressin-like receptor orthologs, the invertebrate
CCAPR, vertebrate and invertebrate Gonadotropin-releasing
hormone receptor (GnRHR) orthologs and several related
neuropeptide receptors. The phylogeny indicated that the tree
had two major clades with the vasopressin-like receptor, CCAPR
and NPSR clustered into one group (100% confidence value) and
all other peptide receptors forming the second cluster, serving as
an outgroup (Figure S1, Table S2). This phylogenetic grouping is
consistent with a recent evolutionary analysis of the GnRHRs
demonstrating that the group of vasopressin-like receptors and the
CCAPR form a monophyletic family which is phylogenetically the
closest to the GnRHR superfamily, while the related peptide
receptors are located basal to this group. However, the study did
not include the NPSR [43]. The Bayesian tree that was used for all
further analyses in our study contained the NPSR, the vertebrate
and invertebrate vasopressin-like receptors, the CCAPR and the
GnRHR orthologs. The tree indicated a topology wherein each
receptor type converged to form well defined clusters with high
confidence values. The GnRHR cluster was used as an outgroup
(Figure 1). The major clades include the known vertebrate NPSR
and the invertebrate CCAPRs. The vasopressin-like receptors
including the vertebrate and invertebrate orthologs form a distinct
cluster (100% confidence value) and are located basal to the
NPSR/CCAPR group. The subclades within the vasopressin-like
receptor clade were in clear agreement with the known receptor
specific functional differences and phylogeny described for the four
vertebrate subtypes and the invertebrate orthologs (Conopressin,
Inotocin, Isotocin, Annetocin, Mesotocin and Cephalotocin
receptors) of this large group [44,45]. An identical topology was
observed for the phylogenetic tree obtained using the maximum
likelihood approach (Figure S2).
The tree also supports the orthology of the putative NPSR-like
receptors identified in the lancelet and acorn worm. These
sequences are monophyletic with the vertebrate NPSR cluster with
good confidence value of 100% and 95%, respectively. So far the
NPSR has been reported to be specific to the tetrapods. However,
identification of NPSR-like sequences in lancelet and acorn worm
indicates that the common ancestor for a NPSR-like gene might
date back to the emergence of the deuterostomes. It is significant
that the lancelet and the acorn worm are the closest extant
relatives of the chordates and that the topology of the NPSR/
NPSR-like cluster follows the expected topology of the ‘tree of life’.
Our annotation of the two invertebrate sequences as NPSR-like is
further supported by the recent discovery of the NG peptide family
[26]. The NG peptide (NGFFFamide-like) and the vasopressin/
oxytocin-like peptide precursors share a common domain
Evolution of Neuropeptide S Receptor
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34046Figure 1. Phylogenetic relationship of the NPSR, CCAPR, GnRHR and vasopressin-like receptors from vertebrates and
invertebrates. Bayesian tree of NPSR (red), invertebrate NPSR-like receptor (orange), CCAPR (green), V1AR (blue), V1BR (blue), OTR (blue), V2R
(blue), GnRHR (vertebrate and invertebrate Gonadotropin releasing hormone receptor) and VPR (invertebrate vasopressin-like receptor) (blue)
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by a C-terminal neurophysin domain although the NG peptide is
structurally unrelated to the cyclic, amidated vasopressin/
oxytocin-like peptide. However, the NPS precursor does not
contain the C-terminal neurophysin domain and the NPS is not
cyclic or amidated. Furthermore, the origin of the vasopressin/
oxytocin-like peptide precursors and their receptor systems can be
dated back to a common ancestor of bilateral animals, 640–760
million years ago [45–48]. In contrast, the NG peptide precursors
exist in the lancelet and the acorn worm, but not in cnidarians,
protostomes, urochordates or vertebrates, whereas the NPS
precursors are specific to the tetrapods [25,26]. Strikingly, the
N-terminal of the human NPS peptide (SFRNGVGTGMK-
KTSFQRAKS), which is critical for its biological activity, shares
sequence identity with the NG peptides (SFRNGVamide in the
lancelet and NGFYNamide in the acorn worm) suggesting that the
NG peptides may be invertebrate homologs of the vertebrate NPS
[26]. One hypothesis that follows is that the lancelet and acorn
worm NPSR-like sequences identified in our study are putative
receptors for the invertebrate NG peptides. It can be speculated
that the relationship within the NPSR/NPSR-like group might be
a case of receptor-ligand coevolution wherein the invertebrate
NPSR-like sequences have evolved to recognize the NG peptide,
while the evolutionarily related vertebrate NPSR recognizes the
NPS peptide. Absence of the gene encoding for NPSR-like
sequences in urochordates and in marine vertebrates including
agnathans, chondrichthyes and teleosts suggests the loss of gene in
multiple lineage. The other hypothesis is that the NPS/NPSR
system in the vertebrates and NG peptide/NPSR-like system in
the invertebrates are indeed homologous, although the physiolog-
ical functions and peptide domain organization have diverged and
the system as a whole or partly, was lost in some lineages. This
hypothesis is also possible since no species seem to have both the
NPS and NG peptide systems. An alternative explanation is that a
specialized NPSR first evolved in the tetrapods and is related to
the invertebrate NPSR-like sequences by convergent evolution.
Based on the available data, it is not possible to derive conclusions
on the nature of relationships between the invertebrate NPSR-like
and vertebrate NPSR or on the origin and the common ancestor
of the NPSR. While the availability of more basal chordate
genomes may aid in obtaining further insights on this issue, a clear
experimental demonstration of the functional cross reactivity of
the receptors will provide further support for the assumption of
ligand-receptor coevolution in the NPSR-NPS/NPSR-like-NG
peptide system. There are several clear examples of peptide
receptor/ligand coevolution in the vertebrates and in the insects,
where an ancestral receptor and ligand gene duplicate several
times followed by mutations and evolutionary selection leading to
different signaling systems [44,49–52].
Conserved residues in the NPSR/NPSR-like sequences
The NPSR/NPSR-like sequences range from 370 to 394 amino
acids in length. The two NPSR-like sequences share pairwise
sequence identities in the range 35–40% across the entire
sequence and 40 to 52% in the transmembrane helices (TM), in
a multiple alignment with NPSR homologs. Several conserved
sequence motifs that may play an important role in function were
identified based on alignment of the identified sequences. Since the
structure-function relationship in the receptor is very poorly
studied, a comparison of regions in the sequence corresponding to
known functional regions in the better-studied paralogous
vasopressin-like receptor sequences was carried out to identify
common as well as selective receptor positions. In all subsequent
analyses and comparisons of residue positions, the residue
numbering includes Ballesteros-Weinstein numbers in superscript
[53,54]. The topology of the regions comprising the three
structural parts, namely the TM, the extracellular loops (ECL)
and the intracellular loops (ICL) have been assigned from the
prediction of TM regions for the human NPSR entry [GenBank:
NP_997055] using the TMHMM program (Figure 2, Figure S3).
Examples of common peptide GPCR conserved motifs include
LxxxD (90
2.46–94
2.50) in TM2, CWxP (286
6.47–289
6.50) in TM6,
NPxxY (326
7.49–330
7.53) in TM7. Cysteine residues (C121
3.25,
C197
4.76) responsible for the formation of disulfide bond between
extracellular loops (ECL1 and 2) are also conserved [55–57].
Examination of the sequence alignment indicates that these
positions are completely conserved in the NPSR/NPSR-likes and
the vasopressin-like receptors. Two conserved motifs WXFG and
DXXCR in ECL1 have been reported to be crucial for ligand
binding and signaling in the neuropeptide receptors [58]. In the
vertebrate NPSR, these regions correspond to highly conserved
WRFTG (108
2.64–112
2.68) and DLVCR (118
3.22–122
3.26) motifs
(Figure 3). However, the NPSR-like sequences appear to have a
modified HRFTX motif in place of WRFTG. Other functionally
important regions for agonist recognition in the vasopressin-like
receptors includes the completely conserved regions FQVLPQ at
the end of TM2 and motif PWG in the ECL2 [56,59,60].
However, the corresponding regions in the NPSR contains
different, albeit highly conserved motifs VNILTD (100
2.56–
105
2.61) and DSY (204
4.83–206
4.85), respectively (Figure 3).
Known functionally important sites specific to NPSRs include
N101
2.57, wherein a N101A mutation led to incomplete
glycosylated forms of the receptor protein without affecting
function and cell surface expression. However, biogenesis of the
receptor could be affected by the altered conformation caused due
to the change at N101
2.57 [58]. This site is completely conserved.
Additionally, structure-activity studies have shown that Asp at
position 105
2.61 could play a direct role in agonist binding by ionic
interactions with a conserved Arg residue at position 3 in the NPS
peptide [22,58]. A negatively charged residue, D/E at this
position, is also completely conserved across the alignment. Site-
directed mutagenesis and transient expression studies on NPSR
indicated that mutation of residue N107
2.63 to Ile, associated with
asthma susceptibility, led to an increase in potency and maximal
efficacy of NPS due to higher level of cell surface receptor density
of mutant compared with wild type receptor [21]. Examination of
the sequence alignment indicates that the human sequence is a
natural variant with an Asn at this position whereas it is Ile in all
other sequences (Figure 3, Figure S3). Thus, sequence conserva-
tion patterns in the NPSR are consistent with previous knowledge
of functional sites and suggest additional examples of group
specific residues.
sequences. The tree was generated using the Bayesian approach in MrBayes 3.1.2 using JTT+F+I+G model. Bayesian posterior probabilities are
marked near branches as a percentage and are used as confidence values of tree branches. Nodes were compressed to represent the animal lineages.
Scale bar represents the number of estimated changes per site for a unit of branch length. The receptor group abbreviations, names and accession
numbers of the sequences and common and binomial names of the species are as listed in Table S2. In this figure and in Figure 4, the sequence
names marked with * and +symbols represent manually corrected sequences at the N terminus and C terminus, respectively. Sequence names
marked with
{ symbol in this figure represent fragmented sequences.
doi:10.1371/journal.pone.0034046.g001
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Gene structure features may aid in supporting the phylogenetic
inference since conservation of exon-intron structure has been
reported in clades of orthologous genes and in families of
paralogous genes and protein superfamilies [61]. A comparative
analysis of the genomic structures of the NPSR, NPSR-like,
CCAPR and the vasopressin-like receptor was carried out (Figure
S3, Figure S4, Data S2). Figure 4 illustrates the distribution,
position and phase of introns within the amino acid sequences. In
general, the NPSR genes are composed of 9 coding exons. In
order to assist comparisons, the introns were named as I to VIII
according to the inserted positions in human NPSR. The positions
of the 8 introns in NPSRs are highly conserved as expected. The
invertebrate NPSR-like sequences are composed of 7 exons. Thus
it appears that the NPSR-like and NPSR sequences contain
similar number of introns. Intron V and intron VIII are lost in the
acorn worm and the lancelet, respectively. Another variation
between the NPSR-like and NPSR include phase change in intron
VI to phase 2 in the NPSR-like. It is noteworthy that both intron
positions and phases in the NPSR-like are highly conserved to that
in the NPSRs. The CCAPRs contain a mostly conserved set of 6 to
9 exons [62]. Remarkably, several intron positions and phases are
highly conserved across the NPSR, NPSR-like and the CCACPR
(introns I, II, III, IV, VI, VII and VIII). The few intron loss or gain
events that occur in these sequences appear to be dependent on
lineage-specific events. The vasopressin-like receptors are mostly
composed of 2 to 3 exons [56,63,64]. The position of the single
intron in human V1AR is the most conserved among this group of
receptors. This position is about 25 residues away from intron VII
of the human NPSR. Thus, conserved intron gain relative to the
vasopressin-like receptors appears to be a conserved feature of the
NPSR/NPSR-like/CCAPR group of receptors. The presence of
relatively larger number of introns could have a role in alternative
splicing events, transcriptional regulatory events and exon
shuffling [65–67]. Several alternatively spliced GPCR variants
with different TM topology have been shown to exist, although
their biological functions are elusive [68,69]. However, studies
with GnRHR isoforms suggest that the truncated variants may
inhibit the signaling or transport of the wild-type receptor [70]. At
least two alternatively spliced forms of human NPSR have been
identified and found to show different pharmacological profiles
[15].
Remarkably, the gene structure-inferred view of the NPSR/
NPSR-like/CCAPR group of the receptors thus shares basic
topological features with the protein sequence based phylogeny. It
is clear that the NPSR is related to the NPSR-like and the two
receptors are most likely orthologous, although the sampling of
NPSR-like may be insufficient. Furthermore, it is intriguing that
the CCAPR, predominantly identified in the arthropods so far,
should show congruence in their relationship to the NPSR/NPSR-
like group at the level of the protein sequence and the gene
Figure 2. Schematic diagram of the human neuropeptide S receptor. The sequence is drawn and labeled according to the extracellular,
intracellular and transmembrane regions. The boundaries of the three regions were based on the definition of these regions for human NPSR
[GenBank: NP_997055] given by the Ballesteros-Weinstein nomenclature and TMHMM program. The most conserved residue in each transmembrane
helix is denoted with red text. The first and last amino acid residue numbers in each helix is indicated using Ballesteros-Weinstein numbering scheme.
Residues that represent sites of functional divergence between the NPSR and the V1AR, V1BR, V2R and OTR subtypes are marked with outlined
circles. Residue-wise functional divergence of NPSR with each subtype of vasopressin-like receptor is provided in Data S3.
doi:10.1371/journal.pone.0034046.g002
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34046structures. Assuming that the pattern of intron-exon boundaries
are good markers of the history of descent of conserved gene
families, one interpretation from our analyses, albeit highly
speculative, is that the CCAPR is an ortholog of the NPSR/
NPSR-like genes. Further, it follows that the common ancestor to
this receptor group might date back to an ancestral bilateral
animal, concomitant with the emergence of the vasopressin-like
receptors. Finally, an analysis of the gene order of the
chromosomal region containing the NPSR gene revealed the
expected conserved synteny of the NPSR gene loci across the
vertebrates. However, the NPSR-like and CCAPR genes do not
display conserved synteny to the NPSR.
Divergence between vertebrate NPSR and vasopressin-
like receptors
Next, we used an analysis of position-specific rate shift variation
to identify putative amino acid residues that may have contributed
to specific sequence–structural features that distinguish the
vertebrate NPSRs from their closest vertebrate neuropeptide
homologs, the vasopressin-like receptors. Although the ligands are
unrelated, the vasopressin-like receptors were chosen as the closest
paralog of the NPSR for the following reasons. Firstly, the large
scale phylogenetic analysis carried out here indicate that the
vasopressin-like receptors are indeed the phylogenetically closest
group to the NPSR, suggesting a common ancestry with deep
roots. Additional evidence comes from chemogenomic analyses of
human non-olfactory GPCRs which indicate that the NPSR and
the vasopressin-like receptors are clustered in a strongly supported
group, independent of the other peptide receptors [71,72]. The
dendrograms in these analyses used alignments of critical residues
(,30–45 residues) in the TM-binding cavity following the
principle that similar ligands are accommodated by similar
binding pockets. In both studies, the clustering topology for the
receptors reflects ligand affinities thus suggesting strong physico-
chemical homology of the TM-binding cavity between the NPSR
and the vasopressin-like receptors [71,72]. Finally, Gupte et al.,
2004, showed typical GPCR signaling by a chimeric receptor,
V1AR/NPSR, which contained the human V1A receptor with all
three intracellular loops (ICLs) and C terminus replaced by those
of NPSR. The chimeric receptor was functionally responsive to
vasopressin. Furthermore, the engineered construct behaved like a
typical GPCR when expressed in mammalian cell lines and
point mutations made in TM2 were shown to drastically affect
activation. The chimeric receptor created to test signaling of
NPSR was based on the homology of the two receptors and
showed properties including dual signaling by coupling to both Gq
and Gs pathways, consistent with the activation of NPSR by NPS
[8]. The signaling properties of the chimera cannot be ascribed
solely to the presence of the TMs and the ECLs of the V1A
receptor.
An amino acid residue in a cluster of homologous sequences is
deemed functionally important if it is evolutionarily conserved.
Therefore, changes in selective constraints on particular amino
acid sites can be used as a measure of functional divergence of
duplicated genes [42]. Type I functional divergence refers to the
evolutionary process where after duplication, the evolutionary rate
at an amino acid site may increase for functional divergence-
related change in the early stage resulting in related but distinct
functions between the two gene clusters. Typically, in Type I
divergence, an amino acid residue is highly conserved in one
cluster, but highly diverse in the other one, implying that these
sites have undergone altered functional constraints (i.e., different
evolutionary rates). In contrast, Type II functional divergence
between the gene clusters does not result in altered functional
constraints but a radical change in amino acid property between
them (for instance, hydrophobicity, charge, etc). In a typical Type
II case, the homologous site in a duplicate gene cluster is
evolutionarily conserved within each of the clusters while drastic
shift in amino acid property has occurred between the clusters.
Such cluster-specific sites have most likely undergone purifying
selection in the late phase after gene duplication resulting in cluster
specific functional properties. The estimated coefficient of
functional divergence between duplicate genes is defined as the
probability of being related to functional divergence, with a large
value indicating a high level of divergence. Furthermore, a site-
specific profile based on empirical posterior analysis can be used to
predict residues that are likely to be responsible for functional
divergence between the two clusters [42,73,74].
Figure 3. Multiple alignment of functionally divergent sites in the NPSR and vasopressin-like receptors. Samplings of selected
functional divergence-related positions in the region starting from TM2 to the end of ECL3 are shown. Amino acid positions (marked on top) are
identified by Ballesteros-Weinstein numbering corresponding to the residue position in human NPSR. Contiguous blocks of conserved residues in the
NPSR are shown within hollow boxes. Residues associated with Type I and II divergence are marked in blue background and red background,
respectively (Data S3).
doi:10.1371/journal.pone.0034046.g003
Figure 4. Conservation and variability of intron positions and
phases. Schematic of the multiple alignment of amino acid sequences
of the NPSR, NPSR-like and representatives from the CCAPR and
vasopressin-like receptor subtypes are shown. The 0, 1, 2 phase introns
are marked with black, red and green lines, respectively. Introns
corresponding to human NPSR are named I to VIII according to their
positions in the amino acid sequence. The gene structure details of all
sequences indicating exon-intron lengths, intron positions and phases
are presented in Figure S3, S4 and Data S2.
doi:10.1371/journal.pone.0034046.g004
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each from the four vertebrate vasopressin-like receptor subtypes
(V1AR, V1BR, V2R and OTR) were used to estimate the
coefficient of Type I and II functional divergence in four separate
comparisons. Estimates of coefficients of divergence (h) indicate
that the NPSR and vasopressin-like receptor group have indeed
undergone diversification (Table 1, Data S3). The h values for
Type I and II divergence between the NPSR and vasopressin-like
receptor subtypes are significantly larger than zero (Table 1). In
contrast, the h values between the vasopressin-like receptor
subtypes range from 0.32–0.47 (p,0.0001) for Type I and are
not significant for Type II, indicating relatively lower levels of
function divergence between the vasopressin-like receptor subtypes
(data not shown). The predicted sites that contribute to divergence
were mapped onto three structurally distinct regions; TM regions,
the ECLs and the ICLs (Figure 2). A total of 51 Type I divergence
sites with posterior probability ratios ranging between 0.90–0.99
were identified (Data S3). The data indicate that Type I sites are
distributed across all three regions and have distinct patterns of
distribution for each NPSR-vasopressin-like receptor subtype
comparison (Table 1). Furthermore, examination of conservation
patterns in the alignment shows that the Type I sites involved sets
of divergent and conserved sites in both groups suggesting that the
early phase of duplicate evolution continued after the first
duplication into paralogous groups. These findings suggest that
site-specific changes may have occurred because of relaxation of
selective constraints in the sequences of either group. Alternatively,
the conserved sites in either group are indicative of newly acquired
functional constraints that were not present in an ancestral
neuropeptide receptor gene. Among the predicted sites, two have
known pharmacological relevance. For example, Ser288
6.49 in
human NPSR is a significant residue in the four residue motif
CWSP located in TM6 [64]. Missense mutation of the
corresponding residue (A285P) in human V2R was identified to
cause X-linked nephrogenic diabetes insipidus [64,75]. Alanine at
this position is highly conserved in V1AR, V1BR and V2R
(Figure 3). This Type I site was recognized with a posterior
probability of 0.957 and was conserved in the NPSR (Data S3).
Type II divergence sites most probably encode paralog-specific
properties since these modifications occur by adaptive fixation of
variants in either groups. The total number of Type II sites (88
residues) increased significantly compared to Type I sites. These
sites are mostly distributed across the ECLs and the TM regions.
This increase in sites suggests a more pronounced role of adaptive
evolution in the late phase after duplication and divergence of
these receptors. Some of the predicted Type II sites correspond to
residues with experimentally characterized functional role for
agonist or antagonist binding or for receptor activation in the
vasopressin-like receptors (Figure 3). For instance, the conserved
G112
2.68 located in the ECL2 in human NPSR corresponds to
Y115 in V1AR, D103 in V2R and F102 in OTR in pairwise
comparisons. This site in the vasopressin-like receptors is
significant for the selectivity of specific agonist against each
subgroup receptor [56,76–79]. Similarly, the residue R109
2.65 at
the extracellular end of TM2 in NPSR is equivalent to residue
K100 in the V2R that has been shown to influence the binding of
peptide agonist [78]. Besides this, F309
6.70 located on ECL3 of
NPSR is equivalent to G304 in the V2R. G304 has been reported
to be involved in stabilizing the conformation of V2R to enable
species-selective binding of cyclic peptide antagonists [78] (Figure
S3). Similarly, Q225 in V2 receptor, which is critical for Gs
recognition and activation, corresponds to Y230
5.58 in NPSR [80].
It is reasonable to hypothesize that several of these predicted
functionally divergent sites could possibly play a role in the specific
properties of the NPSR.
It must be mentioned here that there is significant overlap of
Type I and Type II sites across the four group-wise comparisons,
namely, a Type I divergent site in the NPSR.V1AR comparison
may represent a Type II site in the NPSR.V2R comparison. A
total of 75 unique sites show either one or both types of functional
divergence, across the groups (Figure 2). Out of these, 9 sites
display divergence across all four subtype comparisons, while 9
sites and 17 sites display divergence across three and two subtype
comparisons, respectively. It is very likely that the divergent sites
that are common across multiple comparisons are hotspots for
changes in evolutionary rates and for selection or relaxation of
constraints in the evolution of functional divergence of the NPSR
and the vasopressin-like receptors. The percentage of occurrence
of divergent sites in each structural domain ranges from 14 to 38%
of the total number of residues comprising the respective domain
(Data S3). It is noteworthy that out of a total of 39 residues in the
ECLs, at least 18 sites display either type of divergence across all
comparisons (Data S3). This includes 23 out of 8 residues in ECL2
and 7 out of 10 residues of ECL3. This data is in good agreement
with the large volume of published GPCR data which indicate that
most of the endogenous ligands of the Rhodopsin family GPCRs
bind within the TM domain close to the ECL2 [71,81]. Out of a
total of 194 residues in the TMs, 44 sites display divergence. TM5
contains the largest percentage of divergent sites (10 out of 26
residues), followed by TM6, TM2 and TM4 (9 out of 31 residues,
7 out of 30 residues and 5 out of 23 residues). These residues in the
ECLs and TM 2, 4, 5 and 6 may thus be sensitive to correlated
residue-ligand binding and/or residue-signal transmission speci-
ficities of the NPSR. These observations are also in general
agreement with well known experimental data on the structural
rearrangements of the TMs 2, 5, 6 and 7 caused by amino acids
acting as ‘micro-switches’ during ligand induced activation [82–
85]. Assuming that the NPSR and the vasopressin-like receptors
are paralogs, it can be speculated that the predicted residues that
are conserved within the NPSR evolved by selection and could be
important for the stability of the structure or act as critical
mediators of the signal transmission though the NPSR. Future
biochemical studies can be focused on experimental verification of
the role of the predicted divergent sites in determining paralog
specific properties.
Table 1. Type I and Type II functional divergence between
the NPSR and vasopressin-like receptor subtypes.
Divergence Comparison h±SE z TM ECL ICL
Type I NPSR . V1AR 0.7460.07 10.22 11 5 2
NPSR . V1BR 0.5260.07 7.84 3 3 6
NPSR . V2R 0.5160.07 7.65 5 4 1
NPSR . OTR 0.6360.07 9.20 5 1 3
Type II NPSR . V1AR 0.5360.06 9.04 12 8 3
NPSR . V1BR 0.446.007 6.42 10 6 2
NPSR . V2R 0.496.07 6.48 11 3 -
NPSR . OTR 0.5460.05 10.4 21 10 1
Note: h denotes the coefficient of functional divergence. SE is standard error. z
score is the value of confidence and is obtained by h/SE. P value is the
probability of the z score, which had a value of ,0.0001 in all comparisons. The
symbol - indicates the absence of divergent sites. Abbreviations: TM –
Transmembrane helices, ECL – Extracellular loops, ICL – Intracellular loops.
doi:10.1371/journal.pone.0034046.t001
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A NPSR-like sequence has been identified at the emergence of
the hemichordate suggesting that the origin of the NPSR-like gene
is much older than previously assumed. Comparative analyses at
the levels of amino acid sequences and gene structures supported
the possible orthology of the NPSR and the NPSR-like, although
studies on the cross reactivity of these receptors with peptide
ligands are required to validate this assumption. Available data
also suggest that the NPSR/NPSR-like is orthologous to the
invertebrate CCAPR and the NPSR/NPSR-like/CCAPR group
is phylogenetically the most closely related to the group of
vertebrate and invertebrate vasopressin-like receptors. Site-specific
analysis suggests divergence between the NPSR and the
paralogous vasopressin-like receptor and has demonstrated that
a majority of functionally divergent sites are located on the
transmembrane helices 2, 4, 5 and 6 and at the extracellular loops.
We conclude that the specific effect of ligand on NPSR signal
transduction may be primarily determined by specific sites or a
combination of the sites predicted in this study. The results may be
used for the design of agonist binding studies, site-directed
mutagenesis and other experiments focused on investigating novel
antagonists of NPSR.
Supporting Information
Figure S1 Phylogenetic relationship of the NPSR and
peptide receptors. Bayesian tree of NPSR (red), invertebrate
NPSR-like receptor (orange), CCAPR (green), V1AR (blue),
V1BR (blue), OTR (blue), V2R (blue), VPR (invertebrate
vasopressin-like receptor) (blue), the vertebrate and invertebrate
GnRHR (gonadotropin releasing hormone receptor), NPFFR
(neuropeptide FF receptor), TACR (tachykinin receptor), the
vertebrate NMUR (neuromedin U receptor), NTSR (neurotensin
receptor), GALR (galanin receptor), KISSR (kisspeptin receptor),
NPBWR (neuropeptide W/neuropeptide B receptor), SSTR
(somatostatin receptor), NPYR (neuropeptide Y receptor) and
the invertebrate AKHR (adipokinetic hormone receptor), ACPR
(adipokinetic hormone receptor/corazonin-related peptide recep-
tors), CrzR (corazonin receptor). The tree was generated using the
Bayesian approach in MrBayes 3.1.2 using JTT+F+I+G model.
Analysis was run for 3000000 generations and every hundredth
tree was sampled, until the average standard deviation of split
frequencies dropped below the stop value of 0.02. Bayesian
posterior probabilities are marked near branches as a percentage
and are used as confidence values of tree branches. Nodes were
compressed to represent the animal lineages. Scale bar represents
the number of estimated changes per site for a unit of branch
length. The receptor group abbreviations, names and accession
numbers of the sequences and common and binomial names of the
species are as listed in Table S2. The sequence names marked with
* and +symbols represent sequences manually corrected at the N
terminus and C terminus, respectively.
(TIF)
Figure S2 Phylogenetic relationship of the NPSR,
CCAPR, GnRHR and vasopressin-like receptors from
vertebrates and invertebrates. Maximum likelihood tree of
NPSR (red), invertebrate NPSR-like receptor (orange), CCAPR
(green), V1AR (blue), V1BR (blue), OTR (blue), V2R (blue),
GnRHR (vertebrate and invertebrate Gonadotropin releasing
hormone receptor) and VPR (invertebrate vasopressin-like recep-
tor) (blue) sequences. The tree was generated using the maximum
likelihood method in MEGA5.0 and bootstrap test was carried out
with 500 replicates Best-fit model (JTT+I+G+F) was selected by
ProtTest v2.4. Numbers on the nodes represents the bootstrap
values and the clades possessing less than 50% bootstrap support
were not marked. Nodes were compressed to represent the animal
lineages. Scale bar represents the number of estimated changes per
site for a unit of branch length. The receptor group abbreviations,
names and accession numbers of the sequences and common and
binomial names of the species are as listed in Table S2. The
sequence names marked with * and +symbols represent sequences
fragmented at the N terminus and C terminus, respectively.
Sequence names marked with
{ symbol in this figure represent
fragmented sequences.
(TIF)
Figure S3 Multiple sequence alignment of NPSR, NPSR-
like and representative CCAPR sequences.
(PDF)
Figure S4 Gene structure representation of NPSR,
NPSR-like and representative CCAPR, V1AR, V1BR,
V2R and OTR sequences.
(PDF)
Table S1 List of identified neuropeptide S receptors.
(DOC)
Table S2 Accession numbers of all protein sequences
used in the phylogenetic analyses.
(DOC)
Data S1 Amino acid sequences of NPSR and NPSR-like
sequences in FASTA format.
(DOC)
Data S2 Length of exon-intron regions in the NPSR,
NPSR-like and representative CCAPR, V1AR, V1BR,
V2R and OTR sequences.
(XLS)
Data S3 Functional divergence between NPSR and
vertebrate vasopressin-like sequences. Sheet 1: List of
Accession numbers of the vasopressin-like receptor subtype
sequences used in analysis of Type I and Type II functional
divergence. Sheet 2: Site specific profile for predicting amino acid
residues responsible for Type I functional divergence between
NPSR and V1AR, V1BR, V2R, and OTR groups, respectively,
measured by posterior probability. Sheet 3: Site specific profile for
predicting amino acid residues responsible for Type II functional
divergence between NPSR and V1AR, V1BR, V2R, and OTR
groups, respectively, measured by posterior probability. Sheet 4:
Type I functionally divergent sites predicted between NPSR and
V1AR, V1BR, V2R and OTR receptor subtypes, respectively and
their location in NPSR domain topology. Sheet 5: Type II
functionally divergent sites predicted between NPSR and V1AR,
V1BR, V2R and OTR receptor subtypes, respectively and their
location in NPSR domain topology. Sheet 6: Percentage of
occurrence of Type I and /or Type II divergent sites across
structural domains of human NPSR.
(XLS)
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